Cat. #151161
Anti-MUC1 [SM3]
Cat. #: 151161
Sub-type: Primary antibody
Unit size: 100 ug
Availability: 1-2 weeks
Target: Mucin1 (MUC1)
Class: Monoclonal
Application: ELISA ; FACS ; IHC
Reactivity: Human
Host: Mouse
£300.00
This fee is applicable only for non-profit organisations. If you are a for-profit organisation or a researcher working on commercially-sponsored academic research, you will need to contact our licensing team for a commercial use license.
Contributor
Inventor: Joyce Taylor-Papadimitriou ; Joy Burchell
Institute: Cancer Research UK, London Research Institute: Lincoln's Inn Fields
Tool Details
*FOR RESEARCH USE ONLY (for other uses, please contact the licensing team)
- Name: Anti-MUC1 [SM3]
- Alternate name: ADMCKD, ADMCKD1, Breast carcinoma associated antigen DF3, Breast carcinoma-associated antigen DF3, CA 15-3, CA15 3, CA15 3 antigen, CA15.3, Cancer antigen 15-3, Carcinoma associated mucin, Carcinoma-associated mucin, CD 227, CD227
- Cancer: Digestive / Gastrointestinal cancer
- Cancers detailed: Breast cancer;Ovarian;Colon;Broadly Applicable
- Research fields: Cancer;Cell biology;Cell signaling and signal transduction
- Clone: SM3
- Tool sub type: Primary antibody
- Class: Monoclonal
- Conjugation: Unconjugated
- Strain: Balb/c
- Reactivity: Human
- Host: Mouse
- Application: ELISA ; FACS ; IHC
- Description: SM3 antibody recognises this under-glycosylated form of MUC1 and is therefore tunour specific and may be relevant for breast cancer therapy. SM3 also detects MUC1 within colon and ovarian cancer and most adenocarcinomas and may be used for immunohistochemistry (reactive with methacarn fixed tissue), and immunotargeting.
- Immunogen: Hydrogen fluoride deglycosylated milk mucin.
- Isotype: IgG2a kappa
- Myeloma used: P3X63Ag8.653
- Recommended controls: MCF7 cells (FACS) or human breast carcinoma (IHC)
Target Details
- Target: Mucin1 (MUC1)
- Tissue cell line specificity: MCF7 cells (FACS) or human breast carcinoma (IHC)
- Target background: MUC1 is a large cell surface mucin glycoprotein expressed by most glandular and ductal epithelial cells and some hematopoitic cell lineages. In the vast majority of human carcinomas, this protein is upregulated, poorly glycosylated and appears on the cell surface in a non-polarised fashion.
Applications
- Application: ELISA ; FACS ; IHC
Handling
- Format: Liquid
- Concentration: 1 mg/ml
- Unit size: 100 ug
- Storage buffer: PBS with 0.02% azide
- Storage conditions: -20° C
- Shipping conditions: Shipping at 4° C
Related Tools
- Related tools: Anti-MUC1, Recombinant [SM3]
References
- Geng et al. 2013. Cell Mol Bioeng. 6(2):148-159. PMID: 23805168.
- Targeting Underglycosylated MUC1 for the Selective Capture of Highly Metastatic Breast Cancer Cells Under Flow.
- Srensen et al. 2006. Glycobiology. 16(2):96-107. PMID: 16207894.
- Chemoenzymatically synthesized multimeric Tn/STn MUC1 glycopeptides elicit cancer-specific anti-MUC1 antibody responses and override tolerance.
- Brockhausen et al. 1995. Eur J Biochem. 233(2):607-17. PMID: 7588808.
- Mechanisms underlying aberrant glycosylation of MUC1 mucin in breast cancer cells.
- Burchell et al. 1993. Epithelial Cell Biol. 2(4):155-62. PMID: 7505698.
- Effect of modification of carbohydrate side chains on the reactivity of antibodies with core-protein epitopes of the MUC1 gene product.
- Burchell et al. 1989. Int J Cancer. 44(4):691-6. PMID: 2477336.
- A short sequence, within the amino acid tandem repeat of a cancer-associated mucin, contains immunodominant epitopes.
- Burchell et al. 1987. Cancer Res. 47(20):5476-82. PMID: 2443241.
- Development and characterization of breast cancer reactive monoclonal antibodies directed to the core protein of the human milk mucin.
